In ECHELON-2, adding BV to CHP significantly improved OS in CD30-positive PTCL; however, the trial was dominated by Anaplastic large cell lymphoma (ALCL), leaving the effect size in non-ALCL subtypes (AITL and PTCL-NOS) less certain. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.